Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Gardner

Neurology Cape Girardeau, MO Medical Doctor

NPI 1346251436 CMS profile 152134

3250 Gordonville Rd Ste 450, Cape Girardeau, MO 63703

Open in the dashboard

General payments

$33,046

269 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Gardner of Cape Girardeau, MO is reported in the CMS Open Payments database as having received $33,046 across 269 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $338 8
2024 General $433 12
2023 General $2,984 20
2022 General $6,055 41
2021 General $8,851 99
2020 General $11,022 26
2019 General $3,363 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Gardner
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Robert Gardner were reported at $338. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Robert Gardner Neurology median Middle half National median
2019 $3,363 $474 $118–$2,177 $163
2020 $11,022 $367 $82–$2,309 $114
2021 $8,851 $438 $104–$2,547 $132
2022 $6,055 $442 $103–$2,388 $149
2023 $2,984 $464 $119–$2,312 $160
2024 $433 $468 $119–$2,323 $164
2025 $338 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $25,270 31 payments
  2. AbbVie, Inc. $3,419 43 payments
  3. UCB, Inc. $750 32 payments
  4. Biogen, Inc. $496 15 payments
  5. Medtronic, Inc. $386 5 payments
  6. Kyowa Kirin, Inc. $324 15 payments
  7. ACADIA Pharmaceuticals Inc $273 13 payments
  8. EMD Serono, Inc. $251 21 payments
  9. Novartis Pharmaceuticals Corporation $233 6 payments
  10. Biohaven Pharmaceuticals, Inc. $210 16 payments
  11. Other $1,435 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,646 11 payments
  2. Food and Beverage $5,940 246 payments
  3. Travel and Lodging $2,183 8 payments
  4. Consulting Fee $1,150 2 payments
  5. Education $127 2 payments
Products named General payments · program years 2019–2025
  1. AJOVY Central Nervous System $22,692 22 payments
  2. UBRELVY $3,243 36 payments
  3. QULIPTA $2,705 9 payments
  4. Ajovy Central Nervous System $2,344 7 payments
  5. PERCEPT PC BRAINSENSE $386 5 payments
  6. NOURIANZ $324 15 payments
  7. Briviact $261 19 payments
  8. TYSABRI $226 4 payments
  9. NURTEC ODT $210 16 payments
  10. Mavenclad $202 17 payments
  11. Other $2,943 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Psychiatry & Neurology: 100

Drug cost

$11,769

Median for Psychiatry & Neurology: $2,986

Branded share of claims

100%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aimovig Autoinjector Erenumab-Aooe Brand 16 $11,769

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
  • ACADIA Pharmaceuticals Inc $111
$111 — —
Rystiggo
  • UCB, Inc. $97
$97 — —
NOURIANZ
  • Kyowa Kirin, Inc. $48
$48 — —
Zilbrysq
  • UCB, Inc. $27
$27 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record